HKTDC
9.4.2024 10:55:30 CEST | Business Wire | Press release
Hong Kong Trade Development Council:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240408808037/en/
HKTDC Hong Kong Gifts & Premium Fair, Hong Kong International Printing & Packaging Fair & DeLuxe PrintPack Hong Kong will be held on 27-30 April (Photo: Business Wire)
HKTDC Hong Kong Gifts & Premium Fair
Featuring a curated selection of gift and premium products from around 4000 exhibitors from 21 countries and regions, the fair will be held at the Hong Kong Convention and Exhibition Centre from 27-30 April, with the online matching services “Click2Match” available from 20 April to 7 May. It offers an ideal platform for exhibitors to showcase their latest products, and foster networking and collaboration among industry professionals.
The Hall of Fine Designs will return as a convergence of reputed global brands, including Red A (Hong Kong), Tiny Memory (Hong Kong), YASHICA (Japan) and more. The pavilion formed by Hong Kong Exporters' Association will showcase the design skills and branding excellence of local product designers. Winning works from the Hong Kong Smart Design Awards will also be displayed to highlight the creativity and flair of Hong Kong brands to global industry players.
The anticipated Cultural & Creative Corner will captivate visitors with its vibrant showcase of designer brands and products with unique styles. Catering to the latest trends, the brand-new Outdoor & Sporting Goods zone will showcase a series of products including camping gear, dance shoes, and sporting goods.
To keep visitors abreast of the latest market information and encourage networking, there will be seminars hosted by industry players and associations to share insights on areas crucial to the sector’s development such as consumer market trends, sustainability and silver economy.
Hong Kong International Printing & Packaging Fair & DeLuxe PrintPack Hong Kong
Jointly organised by the Hong Kong Trade Development Council and CIEC Exhibition Company (HK) Limited, the two printpack Fairs will be held from 27-30 April at AsiaWorld-Expo, with the online matching services “Click2Match” available from 20 April to 7 May.
The Printing & Packaging Fair is a premier marketplace to source printing and packaging equipment, products and services. As global demand for luxury packaging grows, the acclaimed World of DeLuxe PrintPack Zone at the Fair will spin off and launch as DeLuxe PrintPack Hong Kong this year. Together, the two Fairs will host around 500 exhibitors, offering a comprehensive showcase of industry-leading solutions.
Highlighted Zones:
- Green Printing & Packaging: bio-degradable materials, upcycled products and innovative green solutions
- Food & Beverage Packaging: functional solutions designed for fresh, chilled, and processed food
- E-commerce Packaging: creative solutions for enterprises to capture e-tailing opportunities
The debut DeLuxe PrintPack will present an array of printing and packaging solutions tailored for luxury goods including jewellery, watches, cosmetics, gourmet food, and wine.
Forums and networking activities will be held share industry trends, sustainable designs and the impact of deluxe packaging on brand identity. Award-winning entries from the Hong Kong Print Awards, the Hong Kong Digital Printing Award and the GAAHK x PolyU Design - Packaging Design will be presented to showcase innovations in printpack design and production.
Register Now: https://tinyurl.com/2jrph7z2
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408808037/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom